Abbott ARCHITECT Assays

combining-clinical-chemistry-immunoassay-testing-d-19-0322
abbott-architect-analyzer-18-2301

Achieve Measurably Better Healthcare Performance

Abbott™ ARCHITECT™ Analyzers offer fast, reliable test results for HIV, hepatitis, syphilis, cardiac conditions, diabetes, sepsis, and more. This single-instrument platform combines both clinical chemistry and immunoassay testing, with analyzers that support labs of all sizes. More than 150 different tests are currently available for ARCHITECT and more are in development.

Download Abbott ARCHITECT Assay Menu (PDF, 241KB)

Contact an Account Manager

Complete the form to request more information about purchasing Abbott ARCHITECT and Assays.

* = required field

thermo-fisher-scientific-logo

By submitting your data, you agree to our Privacy Policy.

© Thermo Fisher Scientific, Inc. All Rights Reserved.

 

HIV Testing Raises Awareness 

hiv-testing-stats-19-0322

HIV still affects more than 1.1 million people in the U.S., and nearly 40% of new infections are transmitted by individuals living with undiagnosed HIV. Help protect your patients by establishing an early testing initiative with the Abbott fourth-generation HIV assays.

The U.S. Centers for Disease Control and Prevention (CDC) recommend screening patients at high risk at least once per year with an FDA-approved antigen/antibody combination immunoassay that detects HIV-1 and HIV-2 antibodies and the HIV-1 p24 antigen. Additionally, the U.S. Preventative Services Task Force (USPSTF) recommends that clinicians screen patients between the ages of 15 and 65 and pregnant women.

  More

Learn More

Syphilis on the Rise

syphilis-rise-stats-19-0322

Recently, clinicians have started to test for syphilis using treponemal-based tests first, and then test only the reactive samples with a non-treponemal method to determine disease activity. This is a change from the traditional sequence of events, and the automated methods offer faster result turn-around times.

The number of primary and secondary (P&S) syphilis cases reported in the U.S. grew from a rate of 4.5 per 100,000 in 2011 to 7.5 per 100,000 in 2015 — a 66.7% increase. The U.S. Preventative Services Task Force (USPSTF) recommends syphilis screening for pregnant women and those at increased risk of infection.

  More

Learn More

Identifying Hepatitis C Infections

hepatitis-c-stats-19-0322

The CDC estimates that roughly 3.2 million Americans are infected with hepatitis C (HCV). However, surveillance has demonstrated that up to 75% of those infected are undiagnosed.

The USPSTF recommends a one-time screening for patients born between 1945 and 1965, and also screening for those at high risk. According to the CDC, a one-time screening program could identify as many as 800,000 infected individuals.

Manage Sepsis with Procalcitonin

sepsis-procalcitonin-stats-19-0322

Studies have shown that procalcitonin is a more accurate diagnostic parameter for sepsis that better predicts mortality and serves as a more reliable biomarker than C-reactive protein, interleukins, or lactate levels.

Sepsis incurs the highest hospitalization costs in the U.S., with annual expenses of over $24 billion. In severe cases, patients with sepsis progress to septic shock, where mortality rates can increase by 8% every hour that antimicrobial treatment is delayed.

  More

Learn More

Abbott Logo

About Abbott

Abbott’s holistic suite of solutions can help you optimize operational, clinical, and financial performance, update your work processes, and transform outdated business relationships into value-creating collaborations. Because when barriers are removed, the whole system works better.

Shop Now